OKYO Pharma Limited (NASDAQ: OKYO) just commenced a Phase II clinical trial and with top-line data to be published by year-end, this catalyst could pr...
Muscle Maker, Inc. (NASDAQ: GRIL) is set to grow revenue from $162M in 2022 to over $1B in 2024, with a substantial rise in adjusted net income, there...
The Camber Energy, Inc. (NYSE: CEI) pending merger with Viking Energy Group Inc. (OTC:VKIN) could drive CEI's market cap much higher as the combined c...
In this text-only issue of The Goldman Guide, see what types of stocks we recommend selling AND buying. Also, interesting intel on sentiment and tradi...
In what may be the best kept secret on Wall Street, emerging MedTech Firm HippoFi, Inc. (OTC:ORHB) is experiencing unprecedented sales growth. And tha...
Don't Sell in May and Go Away In this text-only issue of The Goldman Guide, see what types of stocks we recommend selling AND buying. Also, interestin...
GoldmanSmallCap
New report on $OKYO w/$5.50 price target. Upcoming milestones to drive major re-valuation of stock in 2023 and poss… https://t.co/DvvnqM2sfp
GoldmanSmallCap
New rept on $GRIL w/conservative $4.50 target in 6-9 mos. Enviable transformative situation. Investors will be hung… https://t.co/jsBU3C9aj4
GoldmanSmallCap
New report out on $ORHB w/price target. Best kept secret on Wall Street. Undervalued, underfollowed medtech provide… https://t.co/Bx8guoh5Tn
GoldmanSmallCap
New report on $CHUC w/near term price tgt more than 3x closing price. Huge top-line growth ahead, and strong op inc… https://t.co/ppIlkhBtZI
GoldmanSmallCap
New report on $CEI w/price target. Pending merger with $VKIN a long time coming but all legacy news shown in underv… https://t.co/OqCI2KnbSr